New mechanism for increased levels of metastatic chemokine receptors revealed
Thomas Slagsvold, a postdoctoral fellow in Harald Stenmarks group, has recently published in EMBO Journal (impact factor 10,053) a paper that sheds light on how the cellular levels of the chemokine receptor CXCR4 are increased in cancers. This issue is of considerable interest because enhanced expression of CXCR4 has been strongly associated with metastasis of breast cancer cells to lung tissue.
Recent studies by others had shown that HER2, a member of the epidermal growth factor receptor family that strongly increases the aggressiveness of breast tumours, causes increased cellular CXCR4 levels by stimulating PI 3-kinase, an enzyme that phosphorylates a specific phospholipid to yield the lipid product known as PIP3. A collaborative project between Stenmarks group and Adriano Marchese, a CXCR4 expert at the Loyola University of Chicago, had previously revealed that the ubiquitin ligase AIP4 is crucial for the degradation of CXCR4 by ubiquitinating the receptor and thus targeting it for degradation in lysosomes (Marchese et al., Dev.Cell 2003). In the present EMBO Journal paper, Slagsvold and co-workers collaborated with Marchese to show that a protein kinase activated by PIP3, PDK1, activates another protein kinase, CISK. CISK in turn regulates AIP4 through phosphorylation of specific residues and thus prevents targeting of CXCR4 to the degradative lysosomes. This is likely to be part of the reason why CXCR4 levels are increased in HER2-overexpressing tumours and might provide a novel therapeutic target.
From major journals, first or last author from the Institute for Cancer Research
Hauge A, Gaustad JV, Huang R, Simonsen TG, Wegner CS, Andersen LMK, Rofstad EK(2019) DCE-MRI and Quantitative Histology Reveal Enhanced Vessel Maturation but Impaired Perfusion and Increased Hypoxia in Bevacizumab-Treated Cervical Carcinoma Int J Radiat Oncol Biol Phys(in press) DOI 10.1016/j.ijrobp.2019.03.002, PubMed 30858145
Öjlert ÅK, Halvorsen AR, Nebdal D, Lund-Iversen M, Solberg S, Brustugun OT, Lingjaerde OC, Helland Å(2019) The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery Mol Oncol(in press) DOI 10.1002/1878-0261.12475, PubMed 30854794
Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M(2019) A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy Haematologica(in press) DOI 10.3324/haematol.2018.209080, PubMed 30846496